Related references
Note: Only part of the references are listed.Antithrombotic Therapy for VTE Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines
Clive Kearon et al.
CHEST (2012)
Impact of Various Body Weights and Serum Creatinine Concentrations on the Bias and Accuracy of the Cockcroft-Gault Equation
Mary A. Winter et al.
PHARMACOTHERAPY (2012)
Anticoagulating obese patients in the modern era
Jignesh P. Patel et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Evaluation of therapeutic anticoagulation with enoxaparin and associated anti-Xa monitoring in patients with morbid obesity: a case series
Eli N. Deal et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2011)
Estimation of creatinine clearance in morbidly obese patients
Jasmina A. Demirovic et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2009)
Low-Molecular-Weight Heparins in Renal Impairment and Obesity: Available Evidence and Clinical Practice Recommendations Across Medical and Surgical Settings
Edith A. Nutescu et al.
ANNALS OF PHARMACOTHERAPY (2009)
Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency
N. P. Clark
THROMBOSIS RESEARCH (2008)
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients
S Schulman et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
Dosage of enoxaparin among obese and renal impairment patients
A Bazinet et al.
THROMBOSIS RESEARCH (2005)
Heparin and low-molecular-weight heparin - The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
J Hirsh et al.
CHEST (2004)
Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: Analysis from the ESSENCE and TIMI 11B studies
SA Spinler et al.
AMERICAN HEART JOURNAL (2003)
Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin
SL Chow et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2003)
The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers
GJ Sanderink et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2002)
Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease
G Merli et al.
ANNALS OF INTERNAL MEDICINE (2001)
Dosing and monitoring of low-molecular-weight heparins in special populations
BA Duplaga et al.
PHARMACOTHERAPY (2001)
Share Paper
